Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.94 Consensus Price Target from Analysts

Lucid Diagnostics Inc. (NASDAQ:LUCD) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $3.9375.

Several analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lucid Diagnostics in a research note on Monday, December 29th. Ascendiant Capital Markets boosted their target price on Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Needham & Company LLC reiterated a “buy” rating and set a $3.00 price target on shares of Lucid Diagnostics in a report on Thursday, November 13th. Finally, Wall Street Zen downgraded Lucid Diagnostics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th.

Lucid Diagnostics Price Performance

Shares of NASDAQ LUCD opened at $1.22 on Monday. Lucid Diagnostics has a 1 year low of $0.95 and a 1 year high of $1.80. The stock has a market cap of $167.97 million, a PE ratio of -1.17 and a beta of 1.22. The firm has a fifty day moving average price of $1.14 and a 200-day moving average price of $1.12.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The business had revenue of $1.21 million during the quarter, compared to analyst estimates of $1.35 million. On average, research analysts expect that Lucid Diagnostics will post -0.84 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Perkins Capital Management Inc. bought a new stake in shares of Lucid Diagnostics in the third quarter valued at about $1,138,000. Traphagen Investment Advisors LLC bought a new position in shares of Lucid Diagnostics during the second quarter valued at approximately $34,000. JPMorgan Chase & Co. increased its holdings in Lucid Diagnostics by 71,026.1% during the second quarter. JPMorgan Chase & Co. now owns 32,718 shares of the company’s stock valued at $38,000 after buying an additional 32,672 shares during the period. Geode Capital Management LLC increased its holdings in Lucid Diagnostics by 420.3% during the second quarter. Geode Capital Management LLC now owns 1,577,369 shares of the company’s stock valued at $1,814,000 after buying an additional 1,274,194 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in Lucid Diagnostics by 35.7% in the first quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock worth $129,000 after buying an additional 22,727 shares in the last quarter. 74.01% of the stock is currently owned by hedge funds and other institutional investors.

Lucid Diagnostics Company Profile

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.